Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy

NCT05790096 | Unknown Phase 3

• 1 other identifier: FILBLAU1022
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Randomized Study of the Clinical Efficacy and Safety of Filgrastine® in Patients with Breast Cancer Treated with Myelotoxic Chemotherapy. Primary Objective: to evaluate the activity and safety of Filgrastine® in Brazilian patients undergoing adjuvant treatment for breast cancer, with the frequency of grade 4 neutropenia in the first cycle of chemotherapy as the primary endpoint. Secondary Objectives:

• Frequency of febrile neutropenia during treatment;
• Frequency of neutropenia of any degree in the first cycle;
• Frequency of hospitalization during treatment;
• Duration of grade 4 neutropenia in the first treatment cycle;
• Toxicity during treatment;
• Immunogenicity throughout treatment. All endpoints will be descriptively analyzed in both groups of patients. Study design Randomized (2:1), open-label, multicenter study. Chemotherapy will be given on the first day of each cycle of treatment, for a maximum of four to eight cycles, depending on the regimen, patients whose chemotherapy treatment is prolonged beyond this period being withdrawn from the study. Patients will be evaluated through laboratory tests, including complete blood count, biochemistry and anti-filgrastim antibodies.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• frequency of grade 4 neutropenia in the first cycle of chemotherapy in the group of patients treated with Filgrastine®

  1 month

Secondary Outcomes (6)

• Frequency of febrile neutropenia during treatment;

  maximum 5 months

• Frequency of neutropenia of any degree in the first cycle;

  1 month

• Frequency of hospitalization during treatment;

  maximum 5 months

• Duration of grade 4 neutropenia in the first treatment cycle

  1 month

• Adverse event monitoring

  maximum 5 months

Study Arms (2)

Reference Drug - Granulokine®

ACTIVE COMPARATOR

Reference Drug - Granulokine® is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim. Granulokine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization.

Biological: Granulokine

Test Drug - Filgrastine®

EXPERIMENTAL

Test Drug - Filgrastine® is presented in boxes containing vials containing 1 mL of solution for injection and 300 µg of filgrastim. Filgrastine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization.

Biological: Filgrastine

Interventions

Granulokine BIOLOGICAL

Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.

Reference Drug - Granulokine®

Filgrastine BIOLOGICAL

Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.

Test Drug - Filgrastine®

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of the Free and Informed Consent Form by written;
• Female sex;
• Age between 18 and 75 years old;
• Diagnosis of breast cancer confirmed by cytology or histopathology;
• Disease in stages II or III, according to the classification tumor-node-metastasis (TNM);
• Indication of chemotherapy with full dose of one of the regimens eligible;
• Performance status of 0 or 1;
• Appropriate body functions (absolute neutrophil count \[CAN\] ≥1,500/mm³; platelet count ≥150,000/mm³; serum creatinine ≤1.2 mg/dL; bilirubin and transaminases ≤1.5 times the upper limit of normal).

You may not qualify if:

• Previous use of chemotherapy;
• Previous use of filgrastim;
• Prediction of prophylactic or therapeutic use of antibiotics, antifungals or antivirals in the first cycle of chemotherapy;
• Previous radiotherapy involving the pelvis or radiotherapy from any site within the last 6 weeks prior to randomization;
• History of bone marrow transplantation (as a recipient);
• Presence of other neoplasms;
• Presence of severe co-morbidities;
• Recent (\<6 months) or planned participation in other studies clinical trials involving drugs of any nature or in studies of any form of intervention;
• Known intolerance or allergy to any of the components the filgrastim formulations evaluated in the study;
• Pregnancy or lactation (patients of childbearing potential must have a negative serological pregnancy test dated within 7 days prior to randomization).

Sponsors & Collaborators

• Blau Farmaceutica S.A.: lead

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 13, 2023
• First Posted: March 29, 2023
• Study Start: May 1, 2023
• Primary Completion: June 1, 2024
• Study Completion: December 1, 2024
• Last Updated: March 29, 2023

Record last verified: 2023-01